Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
Astellas Pharma said on February 5 that it has filed its complement C5 inhibitor avacincaptad pegol in Japan seeking conditional approval for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).The drug is already approved in the…
To read the full story
Related Article
- Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
- Takeda’s Livmarli, BMS’s Camzyos and More Up for MHLW Panel Review on March 6
February 21, 2025
- Astellas to File Japan NDA for Izervay This Month
February 5, 2025
BUSINESS
- Pfizer Rolls Out Hemophilia Therapy Hympavzi in Japan
March 25, 2025
- Strattera Stock Expected to Run Out as Lilly's Talks with Regulators Drag On
March 24, 2025
- Mitsubishi Seeks Uplizna Nod for IgG4-Related Disease in Japan
March 24, 2025
- Keytruda Filed for Perioperative Use for Head and Neck Cancer in Japan
March 24, 2025
- Departing Employee Stole Personal Data on 5,200 People: MSD
March 24, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…